On July 10, the White House abandoned efforts to eliminate safe-harbor protections for drug rebates in Medicare Part D and Medicaid managed care due to concerns that the change would lead to higher premiums for beneficiaries. (For background on this issue, see our previous blogs.) While the rebate issue is now off the table,Read more
A view from the Center
Deloitte's Life Sciences & Health Care Blog
Filter by category or month:
Back to the future: With increased scrutiny over price increases, the fundamentals of organic growth in biopharma are more important than everby Cameron McClearn, principal, and Tom Yang, principal, Deloitte Consulting LLP
Price increases. This is arguably the most discussed topic in the biopharmaceutical industry today. In January, biopharmaceutical manufacturers raised list prices on more than 250 products.1 In July, 20 companies increased the list prices for more than 40 prescription drugs by an average of 13 percent.2 But are annual price increases a sustainable mechanism for driving future growth in biopharma?Read more
Sometimes a relatively small investment can lead to the development of a product or process that benefits a company, an industry, or even society as a whole. The three-point seat belt, for example, is a simple strap of nylon webbing that protects drivers and passengers from being injured in an accident. This innovation helped to transform safety standards in the automotive industry and has saved millions of lives.Read more
Digital tech and strong patient-advocacy partnerships could be a win-win-win for pharma, advocacy groups, and patientsby Jonathan Fox, Specialist leader, Deloitte Consulting LLP
I’m in Philadelphia this week for the annual EyeForPharma conference where I’ll be moderating a panel looking into how pharmaceutical companies and advocacy groups can take their relationship to the next level. Both sides have something to gain, and the patient could be the biggest winner.
Pharmaceutical companies often collaborate with patient advocacy groups,Read more
As interest in oncology grows, real-world data could help biopharma firms improve clinical research, reduce costsby Brett J. Davis, General Manager & Principal | ConvergeHealth by Deloitte, Deloitte Consulting LLP
Early this year, I attended the annual J.P. Morgan Healthcare conference where investors and biopharmaceutical company executives were excited about the growth of personalized therapies—particularly in oncology. This optimism was somewhat tempered by some of the many challenges in oncology research and development (R&D) and bringing high-cost therapies to market. However, advances in digital health,Read more
There is something about a new year that gives us a clearer vantage point on the trends that might lie ahead. A new year might be an artificial demarcation point, but I use it to reflect on where the health care and innovation market is now, and where it could be headed.
The exponential promise that exists in the life sciences and health care sectors is unprecedented.Read more